In a significant stride towards innovative cancer therapy, Propanc Biopharma, Inc., a front-runner developing novel treatments targeting recurring and metastatic cancers, has recently spotlighted its progress and achievements, particularly shining a light on the success of a compassionate use study. Based in Melbourne, Australia, the biopharmaceutical company has scheduled a corporate update call on March 28, 2024, intending to discuss the recent advancements and the remarkable findings from this study, using its proenzyme therapy.

The promising results from the compassionate use study are particularly striking. Conducted on 46 patients with advanced metastatic cancers of various origins, including prostate, breast, ovarian, and pancreatic cancers, among others, the study used a rectal formulation of pancreatic proenzymes. Impressively, 19 of the 46 patients, equating to 41.3% of the participants, exhibited a significantly longer survival time than initially expected, with their mean survival reaching 9.0 months versus the anticipated 5.6 months. Furthermore, no severe or serious adverse events were associated with the treatment, underscoring its potential as a viable cancer therapy.

Propanc Biopharma’s novel approach hinges on the utilization of pancreatic proenzymes, specifically a mixture of trypsinogen and chymotrypsinogen from bovine pancreas, administered via intravenous injection. The company’s leading asset, PRP, which stands at the core of its research, aims to target and eradicate cancer stem cells, offering hope for patients suffering from a range of solid tumors. To this end, the US Food and Drug Administration (FDA) has granted PRP the Orphan Drug Designation status for the treatment of pancreatic cancer, marking a notable endorsement of its therapeutic potential.

The update call slated for the end of March features an impressive roster of participants from Propanc Biopharma’s management, including Dr. Julian Kenyon, the Chief Scientific Officer and Cofounder, Prof. Klaus Kutz, Acting Chief Medical Officer, Dr. Ralf Brandt, a member of the Scientific Advisory Board and Coinventor, and Mr. James Nathanielsz, the Chief Executive Officer, Executive Chairman, and Chief Financial Officer. Their insights are keenly anticipated, as they are expected to provide deeper understanding into the study’s outcomes, the ongoing development of PRP, and the envisioned path towards initiating a Phase 1b, First-in-Human (FIH) clinical study.

These developments come at a pivotal time in cancer research, as the search for more effective and less invasive treatments is more urgent than ever. With the global cancer burden rising, innovative therapies like PRP could revolutionize the approach to cancer treatment, focusing on eradicating cancer stem cells to prevent recurrence and metastasis.

As Propanc Biopharma moves forward in its journey of pioneering a novel class of cancer treatments, the industry and patients alike watch with bated breath, hopeful for breakthroughs that could transform the landscape of cancer care.